Insight

Giampaolo Bianchini: Join us at the next ESMO Virtual Plenary session!

Photo from Giampaolo Bianchini/Twitter

May 8, 2024, 23:17

Giampaolo Bianchini: Join us at the next ESMO Virtual Plenary session!

Elisa Agostinetto, Research Physician at Institute of Jules Bordet in Brussels, shared a post by Giampaolo Bianchini, Head of the Translational and Immunotherapy Research Group at the San Raffaele Scientific Institute – Milan, on X, adding the following:

“Results from a randomized phase 3 trial will be presented this Thursday at the ESMO Virtual Plenary – intriguing data for all breast oncologists!!”

Quoting Giampaolo Bianchini’s post:

“Join us at the next ESMO Virtual Plenary session!

Is there a new PARPi option for HER2-neg gBRCA1/2mut MBC?
Does a combination of PARPi and antiangiogenic drug (apatinib) improve efficacy?
Are VEGFRi better than bevacizumab?”

Giampaolo Bianchini: Join us at the next ESMO Virtual Plenary session!

Source: Elisa Agostinetto/X and Giampaolo Bianchini/X

antiangiogenic therapy Bevacizumab breast oncology cancer clinical trial Elisa Agostinetto ESMO ESMO Virtual Plenary gBRCA1/2 mutation Giampaolo Bianchini HER2-negative Institute of Jules Bordet metastatic breast cancer OncoDaily Oncology PARP inhibitors Research San Raffaele Scientific Institute VEGFR inhibitors

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL

Bispecific Antibody M701 Offers a Novel Treatment Option for Malignant Ascites

Special Coverage